πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Alzamend Neuro, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Alector, Inc.

Alector, Inc. logo
Market Cap: Medium
Employees: Low

AL001, AL101, AL002, AL003, AL044

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.

Tags: Alzheimer's, Parkinson's, biopharmaceutical, clinical trials, neurodegeneration, therapies

Symbol: ALEC

Recent Price: $1.72

Industry: Biotechnology

CEO: Dr. Arnon Rosenthal Ph.D.

Sector: Healthcare

Employees: 245

Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 415 231 5660

Leadership

  • Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
  • Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
  • Marc Grasso, M.D., Chief Financial Officer
  • Gary Romano, M.D., Ph.D., Chief Medical Officer
  • Danielle Pasqualone, Ph.D., J.D., General Counsel
  • Clare Hunt, M.B.A., Chief People Officer
  • Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
  • Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
  • Norah Conway, Senior Vice President, Portfolio and Program Management
  • Neil Berkley, M.S., M.B.A., Chief Business Officer
  • Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
  • Elizabeth Garofalo, M.D., Board Member
  • Paula Hammond, Ph.D., Board Member
  • Richard H. Scheller, Ph.D., Board Member
  • David Wehner, Board Member
  • Kristine Yaffe, M.D., Board Member
  • Errol De Souza, Ph.D., Board Member
  • Mark Altmeyer, M.B.A., Board Member

Last updated: 2024-12-31

Athira Pharma, Inc.

Athira Pharma, Inc. logo
Market Cap: Lowest
Employees: Low

ATH-1017

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.

Tags: Alzheimer's disease, Parkinson's disease, biopharmaceutical, clinical trials, neurodegeneration

Symbol: ATHA

Recent Price: $0.55

Industry: Biotechnology

CEO: Dr. Mark J. Litton M.B.A., Ph.D.

Sector: Healthcare

Employees: 65

Address: 18706 North Creek Parkway, Bothell, WA 98011

Phone: 425 620 8501

Last updated: 2024-12-31

DURECT Corporation

DURECT Corporation logo
Market Cap: Lowest
Employees: Lowest

ALZET

DURECT Corporation is a biopharmaceutical company that develops medicines based on its epigenetic regulator and pharmaceutical programs. It offers products like ALZET osmotic pumps for laboratory animal research, larsucosterol for treating liver diseases, and POSIMIR for post-surgical pain relief.

Tags: ALZET, POSIMIR, biopharmaceutical, epigenetic, larsucosterol, research

Symbol: DRRX

Recent Price: $0.85

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. James E. Brown D.V.M.

Sector: Healthcare

Employees: 48

Address: 10260 Bubb Road, Cupertino, CA 95014-4166

Phone: 408 777 1417

Last updated: 2024-12-31

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ZYESAMI, NRX-100, NRX-101

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

Tags: CNS disorders, COVID-19 treatment, bipolar depression, clinical-stage pharmaceutical, pulmonary diseases, suicidal behavior

Symbol: NRXP

Recent Price: $1.53

Industry: Biotechnology

CEO: Dr. Jonathan C. Javitt M.D., M.P.H.

Sector: Healthcare

Employees: 2

Address: 1201 Orange Street, Wilmington, DE 19801

Phone: 484 254 6134

Last updated: 2024-12-31

Alto Neuroscience, Inc.

Alto Neuroscience, Inc. logo
Market Cap: Low
Employees: Low

ALTO-100, ALTO-300, ALTO-101, ALTO-203, ALTO-202

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company specializing in psychiatry drug development, with a range of innovative treatments targeting major depressive disorder and cognitive impairments.

Tags: AI-enabled biomarker, MDD, biopharmaceutical, cognitive impairment, drug development, psychiatry, schizophrenia

Symbol: ANRO

Recent Price: $4.20

Industry: Biotechnology

CEO: Dr. Amit Etkin M.D., Ph.D.

Sector: Healthcare

Employees: 78

Address: 369 South San Antonio Road, Los Altos, CA 94022

Phone: (650) 200-0412

Last updated: 2024-12-31

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

ACU193

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for Alzheimer's disease, with a key drug candidate ACU193 targeting amyloid-beta oligomers.

Tags: ACU193, Alzheimer's disease, biopharmaceutical, clinical-stage, immunotherapy

Symbol: ABOS

Recent Price: $1.75

Industry: Biotechnology

CEO: Mr. Daniel J. O'Connell M.B.A.

Sector: Healthcare

Employees: 51

Address: 427 Park Street, Charlottesville, VA 22902

Phone: 434 297 1000

Last updated: 2024-12-31

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. logo
Market Cap: High
Employees: Medium

NUPLAZID

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company committed to the development and commercialization of small molecule drugs to treat unmet medical needs in central nervous system disorders. Key products and developments include NUPLAZID for Parkinson's disease-related psychosis and a diverse pipeline addressing Alzheimer's disease, schizophrenia, Rett syndrome, and pain management.

Tags: Alzheimer's disease, Biopharmaceuticals, CNS disorders, Drug development, NUPLAZID, Pain management, Parkinson's disease, Rett syndrome, Schizophrenia

Symbol: ACAD

Recent Price: $16.69

Industry: Biotechnology

CEO: Ms. Catherine E. Owen Adams

Sector: Healthcare

Employees: 597

Address: 12830 El Camino Real, San Diego, CA 92130

Phone: 858 558 2871

Last updated: 2024-12-31

Alzamend Neuro, Inc.

Alzamend Neuro, Inc. logo
Market Cap: Lowest
Employees: Lowest

AL001 and AL002

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing products for neurodegenerative and psychiatric disorders. Their pipeline includes AL001 for Alzheimer's and psychiatric disorders, and AL002 for Alzheimer's disease using a novel vaccine approach.

Tags: Alzheimer's, biopharmaceutical, clinical trials, mental health, neurodegenerative disorders, psychiatric disorders

Symbol: ALZN

Recent Price: $1.20

Industry: Biotechnology

CEO: Mr. Stephan Jackman

Sector: Healthcare

Employees: 4

Address: 3500 Lenox Road NE, Atlanta, GA 30326

Phone: 844 722 6333

Last updated: 2024-12-31

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Medium

AMX0035

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their leading product, AMX0035, is aimed at ALS treatment.

Tags: ALS, AMX0035, biopharmaceutical, neurodegenerative diseases, therapeutics

Symbol: AMLX

Recent Price: $3.84

Industry: Biotechnology

CEO: Mr. Joshua B. Cohen

Sector: Healthcare

Employees: 384

Address: 43 Thorndike Street, Cambridge, MA 02141

Phone: 617 682 0917

Leadership

  • Linda A. Arsenault, Chief Human Resources Officer
  • Camille L. Bedrosian, MD, Chief Medical Officer
  • Josh Cohen, Co-CEO & Co-Founder
  • James M. Frates, Chief Financial Officer
  • Tom Holmes, Chief Technical Operations Officer
  • Justin Klee, Co-CEO & Co-Founder
  • Gina M. Mazzariello, Chief Legal Officer & General Counsel
  • Rudolph Tanzi, PhD, Founding Chair of the Amylyx SAB
  • Wally Gilbert, Special Advisor
  • Kari Firestone, Director
  • Paul Fonteyne, Director
  • George Milne, Chairman
  • Daphne Quimi, Director
  • Bernhardt G. Zeiher, MD, FACP, FCCP, Director

Last updated: 2024-12-31

Anavex Life Sciences Corp.

Anavex Life Sciences Corp. logo
Market Cap: Medium
Employees: Lowest

ANAVEX 2-73

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company developing drug candidates for CNS diseases, including Alzheimer's, Rett syndrome, and Parkinson's.

Tags: Alzheimer's, CNS diseases, Parkinson's, Rett syndrome, biopharmaceutical, clinical trials, neurodegenerative diseases

Symbol: AVXL

Recent Price: $11.04

Industry: Biotechnology

CEO: Dr. Christopher U. Missling M.B.A., M.S., Ph.D.

Sector: Healthcare

Employees: 40

Address: 51 West 52nd Street, New York, NY 10019

Phone: 844 689 3939

Last updated: 2024-12-31

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

AXS-05, AXS-07, AXS-12, AXS-14

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.

Tags: CNS disorders, biopharmaceutical, clinical trials, depression, fibromyalgia, migraine, narcolepsy

Symbol: AXSM

Recent Price: $84.78

Industry: Biotechnology

CEO: Dr. Herriot Tabuteau M.D.

Sector: Healthcare

Employees: 589

Address: 22 Cortlandt Street, New York, NY 10007

Phone: 212 332 3241

Leadership

  • Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
  • Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
  • Mark Jacobson, MA, CHIEF OPERATING OFFICER
  • Hunter Murdock, Esq., GENERAL COUNSEL
  • ari Maizel, Executive Vice President, Head of Commercial
  • Mark Coleman, MD, DIRECTOR
  • Roger Jeffs, PhD, DIRECTOR
  • Susan Mahony, PhD, MBA, DIRECTOR
  • Mark Saad, DIRECTOR

Last updated: 2024-12-31

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CT1812

Cognition Therapeutics is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for age-related degenerative diseases and central nervous system disorders. Its lead product, CT1812, is designed to treat Alzheimer's disease and dementia with Lewy bodies.

Tags: Alzheimer's disease, biopharmaceutical, central nervous system, retina disorders, small molecule therapeutics

Symbol: CGTX

Recent Price: $0.75

Industry: Biotechnology

CEO: Ms. Lisa Ricciardi

Sector: Healthcare

Employees: 25

Address: 2500 Westchester Avenue, Purchase, NY 10577

Phone: 412 481 2210

Leadership

  • Lisa Ricciardi, Chief Executive Officer​
  • Anthony C. Caggiano, M.D., Ph.D., Chief Medical Officer, Head of R&D
  • John Doyle, Chief Financial Officer
  • Anita Cornet, Head of Quality
  • Theresa Devins, DrPH, Vice President, Clinical Operations
  • Mary Hamby, Ph.D., Vice President, Research
  • Bobby Horn, Corporate Controller
  • Jennifer Iaci, Vice President, Development Operations
  • Steven A. Weissman, Ph.D., Vice President and Head of CMC
  • Jack A. Khattar, CEO
  • Aaron Fletcher, Ph.D.,
  • Brett P. Monia, Ph.D., CEO
  • Ellen B. Richstone,
  • Peggy Wallace,

Last updated: 2024-12-31

CervoMed Inc.

CervoMed Inc. logo
Market Cap: Low
Employees: Lowest

neflamapimod

Cervo Med Inc. is a clinical-stage biotechnology company focused on developing and commercializing drug treatments for neurodegenerative diseases, including neflamapimod for conditions like dementia with Lewy bodies, Alzheimer's diseases, and brain stroke recovery.

Tags: Alzheimer's, biotechnology, brain stroke recovery, dementia, drug development, neurodegenerative diseases

Symbol: CRVO

Recent Price: $2.39

Industry: Biotechnology

CEO: Dr. John J. Alam M.D.

Sector: Healthcare

Employees: 8

Address: 20 Park Plaza, Boston, MA 02116

Phone: 617-744-4400

Last updated: 2024-12-31

Neurogene Inc.

Neurogene Inc. logo
Market Cap: Medium
Employees: Low

NGN-401, NGN-101

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.

Tags: Rett syndrome, biotechnology, gene therapy, genetic medicines, life sciences, neurological diseases, neuronal ceroid lipofuscinosis

Symbol: NGNE

Recent Price: $22.28

Industry: Biotechnology

CEO: Dr. Rachel L. McMinn Ph.D.

Sector: Healthcare

Employees: 91

Address: 535 W 24th Street, New York, NY 10011

Phone: (877) 237-5020

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Nexalin Technology, Inc.

Nexalin Technology, Inc. logo
Market Cap: Lowest
Employees: Lowest

Nexalin Device

Nexalin Technology, Inc., a medical device company, develops neurostimulation products for treating mental health disorders. It markets the Nexalin Device, a therapy for anxiety and insomnia, and is developing Generation 2 for treating substance abuse and other conditions.

Tags: anxiety, clinical trials, insomnia, medical device, mental health, neurostimulation, substance abuse

Symbol: NXL

Recent Price: $2.82

Industry: Medical - Devices

CEO: Mr. Mark White

Sector: Healthcare

Employees: 6

Address: 1776 Yorktown, Houston, TX 77056

Phone: 713 660 1100

Last updated: 2024-12-31

Cassava Sciences, Inc.

Cassava Sciences, Inc. logo
Market Cap: High
Employees: Lowest

simufilam

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead product candidate, simufilam, is a small molecule drug, recently completed Phase 2b clinical trial. The company also develops Sava Dx, a diagnostic to detect Alzheimer's disease.

Tags: Alzheimer's, Sava Dx, biotechnology, drug development, neurodegenerative diseases, simufilam

Symbol: SAVA

Recent Price: $2.40

Industry: Biotechnology

CEO: Mr. Richard Jon Barry

Sector: Healthcare

Employees: 29

Address: 7801 North Capital of Texas Highway, Austin, TX 78731

Phone: 512 501 2444

Last updated: 2024-12-31

Synaptogenix, Inc.

Synaptogenix, Inc. logo
Market Cap: Lowest
Employees: Lowest

Bryostatin-1

Synaptogenix, Inc. is a biopharmaceutical company focused on developing drug candidates for neurodegenerative diseases, including Alzheimer's disease, using Bryostatin-1.

Tags: Alzheimer's disease, Bryostatin-1, biopharmaceutical, clinical development, neurodegenerative diseases

Symbol: SNPX

Recent Price: $3.37

Industry: Biotechnology

CEO: Dr. Alan J. Tuchman M.D., MBA(FAAN)

Sector: Healthcare

Employees: 5

Address: 1185 Avenue of the Americas, New York, NY 10036

Phone: 973 242 0005

Last updated: 2024-12-31

Annovis Bio, Inc.

Annovis Bio, Inc. logo
Market Cap: Low
Employees: Lowest

Buntanetap

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound, Buntanetap, is in clinical trials for various neurodegenerative disorders.

Tags: Alzheimer's disease, Parkinson's disease, clinical trials, drug development, neurodegeneration

Symbol: ANVS

Recent Price: $5.08

Industry: Biotechnology

CEO: Dr. Maria L. Maccecchini Ph.D.

Sector: Healthcare

Employees: 6

Address: 1055 Westlakes Drive, Berwyn, PA 19312

Phone: 610 727 3913

Last updated: 2024-12-31

Denali Therapeutics Inc.

Denali Therapeutics Inc. logo
Market Cap: High
Employees: Medium

BIIB122/DNL151

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. Its pipeline includes treatments for Parkinson's disease, hunter syndrome, ALS, multiple sclerosis, and Alzheimer's disease. It collaborates with companies such as Takeda Pharmaceutical Company and Genentech, Inc.

Tags: ALS, Alzheimer's disease, Parkinson's disease, biopharmaceutical, hunter syndrome, multiple sclerosis, neurodegenerative diseases

Symbol: DNLI

Recent Price: $20.24

Industry: Biotechnology

CEO: Dr. Ryan J. Watts Ph.D.

Sector: Healthcare

Employees: 364

Address: 161 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 866 8548

Last updated: 2024-12-31